[go: up one dir, main page]

AR091739A1 - COMPOSITIONS AND METHODS TO REDUCE CARDIOMETABOLIC RISK - Google Patents

COMPOSITIONS AND METHODS TO REDUCE CARDIOMETABOLIC RISK

Info

Publication number
AR091739A1
AR091739A1 ARP130102472A AR091739A1 AR 091739 A1 AR091739 A1 AR 091739A1 AR P130102472 A ARP130102472 A AR P130102472A AR 091739 A1 AR091739 A1 AR 091739A1
Authority
AR
Argentina
Prior art keywords
compositions
methods
cardiometabolic risk
reduce
reduce cardiometabolic
Prior art date
Application number
Other languages
Spanish (es)
Inventor
S Fineman Mark
D Baron Alain
R A Beeley Nigel
Original Assignee
Elcelyx Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US13/547,022 external-priority patent/US8796338B2/en
Priority claimed from US13/734,966 external-priority patent/US9211263B2/en
Application filed by Elcelyx Therapeutics Inc filed Critical Elcelyx Therapeutics Inc
Publication of AR091739A1 publication Critical patent/AR091739A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/401—Proline; Derivatives thereof, e.g. captopril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Composiciones y métodos que comprenden por lo menos un compuesto biguanida y por lo menos una estatina en combinación con por lo menos un agente activo adicional en combinaciones de dosis fijas para reducir el riesgo cardiometabólico, y para el tratamiento de la enfermedad cardiovascular, en donde el compuesto biguanida está formulado para una liberación retardada.Compositions and methods comprising at least one biguanide compound and at least one statin in combination with at least one additional active agent in fixed dose combinations to reduce cardiometabolic risk, and for the treatment of cardiovascular disease, wherein the Biguanide compound is formulated for delayed release.

ARP130102472 2012-07-11 2013-07-11 COMPOSITIONS AND METHODS TO REDUCE CARDIOMETABOLIC RISK AR091739A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US13/547,022 US8796338B2 (en) 2011-01-07 2012-07-11 Biguanide compositions and methods of treating metabolic disorders
US13/734,966 US9211263B2 (en) 2012-01-06 2013-01-05 Compositions and methods of treating metabolic disorders

Publications (1)

Publication Number Publication Date
AR091739A1 true AR091739A1 (en) 2015-02-25

Family

ID=48833086

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP130102472 AR091739A1 (en) 2012-07-11 2013-07-11 COMPOSITIONS AND METHODS TO REDUCE CARDIOMETABOLIC RISK

Country Status (9)

Country Link
EP (1) EP2872127A1 (en)
JP (2) JP2015522080A (en)
CN (1) CN104780915A (en)
AR (1) AR091739A1 (en)
AU (1) AU2013290100A1 (en)
CA (1) CA2878625A1 (en)
HK (1) HK1210825A1 (en)
IL (1) IL236647A0 (en)
WO (1) WO2014011926A1 (en)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102316875A (en) 2009-02-13 2012-01-11 贝林格尔.英格海姆国际有限公司 SGLT-2 inhibitors for the treatment of type 1 diabetes, type 2 diabetes, impaired glucose tolerance or hyperglycemia
PT2395983T (en) 2009-02-13 2020-07-03 Boehringer Ingelheim Int Pharmaceutical composition comprising a sglt2 inhibitor, a dpp-iv inhibitor and optionally a further antidiabetic agent and uses thereof
UY33937A (en) 2011-03-07 2012-09-28 Boehringer Ingelheim Int PHARMACEUTICAL COMPOSITIONS CONTAINING DPP-4 AND / OR SGLT-2 AND METFORMIN INHIBITORS
CA2812519A1 (en) 2013-04-05 2014-10-05 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof
US11813275B2 (en) 2013-04-05 2023-11-14 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof
HK1213818A1 (en) 2013-04-05 2016-07-15 勃林格殷格翰国际有限公司 Therapeutic uses of empagliflozin
ES2702174T3 (en) 2013-04-05 2019-02-27 Boehringer Ingelheim Int Therapeutic uses of empagliflozin
DK2986304T3 (en) 2013-04-18 2022-04-04 Boehringer Ingelheim Int PHARMACEUTICAL COMPOSITION, TREATMENT PROCEDURES AND USES.
CN109922813A (en) 2016-11-10 2019-06-21 勃林格殷格翰国际有限公司 Pharmaceutical composition, treatment method and application thereof
WO2019128991A1 (en) * 2017-12-26 2019-07-04 Sunshine Lake Pharma Co., Ltd. Lurasidone solid dispersion and preparation method thereof
KR20220046623A (en) 2019-08-12 2022-04-14 메사추세츠 인스티튜트 오브 테크놀로지 Articles and methods for administration of therapeutic agents

Family Cites Families (275)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3536809A (en) 1969-02-17 1970-10-27 Alza Corp Medication method
US3598123A (en) 1969-04-01 1971-08-10 Alza Corp Bandage for administering drugs
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US3916899A (en) 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
JPS58403B2 (en) 1975-07-24 1983-01-06 武田薬品工業株式会社 L- Ascorbine Sanseizaino Seizouhou
US4008719A (en) 1976-02-02 1977-02-22 Alza Corporation Osmotic system having laminar arrangement for programming delivery of active agent
IE58110B1 (en) 1984-10-30 1993-07-14 Elan Corp Plc Controlled release powder and process for its preparation
US5073543A (en) 1988-07-21 1991-12-17 G. D. Searle & Co. Controlled release formulations of trophic factors in ganglioside-lipsome vehicle
US5135757A (en) 1988-09-19 1992-08-04 Edward Mendell Co., Inc. Compressible sustained release solid dosage forms
IT1229203B (en) 1989-03-22 1991-07-25 Bioresearch Spa USE OF 5 METHYLTHETRAHYDROPHOLIC ACID, 5 FORMYLTHETRAHYDROPHOLIC ACID AND THEIR PHARMACEUTICALLY ACCEPTABLE SALTS FOR THE PREPARATION OF PHARMACEUTICAL COMPOSITIONS IN THE FORM OF CONTROLLED RELEASE ACTIVE IN THE THERAPY OF MENTAL AND ORGANIC DISORDERS.
US5120548A (en) 1989-11-07 1992-06-09 Merck & Co., Inc. Swelling modulated polymeric drug delivery device
US5733566A (en) 1990-05-15 1998-03-31 Alkermes Controlled Therapeutics Inc. Ii Controlled release of antiparasitic agents in animals
US5580578A (en) 1992-01-27 1996-12-03 Euro-Celtique, S.A. Controlled release formulations coated with aqueous dispersions of acrylic polymers
US5591767A (en) 1993-01-25 1997-01-07 Pharmetrix Corporation Liquid reservoir transdermal patch for the administration of ketorolac
FR2704146B1 (en) 1993-04-19 1995-07-13 Cripdom Microcapsules of acetylsalicylic acid with controlled release.
US5773025A (en) 1993-09-09 1998-06-30 Edward Mendell Co., Inc. Sustained release heterodisperse hydrogel systems--amorphous drugs
IT1270594B (en) 1994-07-07 1997-05-07 Recordati Chem Pharm CONTROLLED RELEASE PHARMACEUTICAL COMPOSITION OF LIQUID SUSPENSION MOGUISTEIN
FR2725623A1 (en) 1994-10-18 1996-04-19 Flamel Tech Sa MEDICINAL AND / OR NUTRITION MICROCAPSULES FOR PER OS ADMINISTRATION
KR100510614B1 (en) 1997-04-15 2005-08-30 씨에스아이알 Intermediate for the preparation of compound having appetite suppressant activity and process for the preparation thereof
US5891919A (en) 1997-09-19 1999-04-06 Burlington Bio-Medical & Scientific Corp. Denatonium capsaicinate and methods of producing the same
US6180365B1 (en) 1998-11-06 2001-01-30 Smithkline Beecham Corporation Polynucleotide encoding a Mouse 7-transmembrane GPR43 receptor
ITMI991316A1 (en) 1999-06-14 2000-12-14 Cip Ninety Two 92 S A ORAL PHARMACEUTICAL COMPOSITIONS WITH MODIFIED RELEASE OF MESALAZINE
IL132313A0 (en) 1999-10-11 2001-03-19 Yeda Res & Dev Leptin assay
AU2001232132A1 (en) 2000-02-18 2001-08-27 Glaxo Group Limited Novel assay
US20110217394A1 (en) 2000-12-05 2011-09-08 Brett Justin West Iridoid Based Formulations
AU2002307217A1 (en) 2001-03-28 2002-10-15 University Of South Florida Materials and methods for treatment of cancer and identification of anti-cancer compounds
US8030008B2 (en) 2001-04-05 2011-10-04 Senomyx, Inc. Identification of bitter ligands that specifically activate human T2R receptors and related assays for identifying human bitter taste modulators
WO2003057730A1 (en) 2002-01-07 2003-07-17 Euroscreen S.A. Ligand for g-protein coupled receptor gpr43 and uses thereof
US20030171407A1 (en) * 2002-03-07 2003-09-11 Upsher-Smith Laboratories, Inc. Composition for reducing blood glucose and cholesterol
US20060019346A1 (en) 2002-07-29 2006-01-26 Senomyx, Inc. Identification of a novel bitter taste receptor T2R76 that specifically responds to brucine and prop bitter ligands
US7214387B2 (en) * 2002-08-02 2007-05-08 Penwest Pharmaceuticals Company Sustained release formulations of metformin
WO2004033431A2 (en) 2002-10-04 2004-04-22 Arena Pharmaceuticals, Inc. Hydroxypyrazoles for use against metabolic-related disorders
EP1551403B1 (en) 2002-10-10 2009-04-29 Arena Pharmaceuticals, Inc. 5-substituted 2h-pyrazone-3-carboxylic acid derivatives as antilipolytic agents for the treatment of metabolic-related disorders such as dyslipidemia
WO2004038421A2 (en) 2002-10-25 2004-05-06 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with human g protein-coupled receptor 41 (gpr41)
AU2003273994A1 (en) 2002-10-25 2004-05-13 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with g protein-coupled receptor 43 (gpr43)
US7960369B2 (en) 2002-11-08 2011-06-14 Takeda Pharmaceutical Company Limited Receptor function regulator
CN1413582A (en) * 2002-11-29 2003-04-30 贵州圣济堂制药有限公司 Dimethyldiguanide hydrochloride enteric solubility tablet and its preparation method
EP1581555B1 (en) 2002-12-18 2008-04-30 Givaudan SA Chimeric alpha q-gustducin g-proteins
US20060160088A1 (en) 2003-02-17 2006-07-20 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with g protein-coupled receptor 40 (gpr40)
DE10308504A1 (en) 2003-02-26 2004-09-09 Basf Ag Enzymatic production of (meth) acrylic acid esters
WO2004106276A1 (en) 2003-05-30 2004-12-09 Takeda Pharmaceutical Company Limited Condensed ring compound
WO2005011677A1 (en) 2003-06-13 2005-02-10 Arena Pharmaceuticals, Inc. 5-substituted 2h-pyrazole-3-carboxylic acid derivatives as agonists for the nicotinic acid receptor rup25 for the treatment of dyslipidemia and related diseases
WO2005009351A2 (en) 2003-07-17 2005-02-03 Santé International, Inc. Dietary supplement for promoting control of blood-sugar levels and associated pathology in type 2 diabetics
AU2003269484A1 (en) * 2003-09-11 2005-03-29 Biocon Limited Salt of atorvastatin with metformin
WO2005028488A1 (en) 2003-09-12 2005-03-31 Quatrx Pharmaceuticals Co. Heteroaryl phosphinyl and thiophosphinyl compounds for regulation of glucose, triglycerides, and ldl/hdl levels
TWI258478B (en) 2003-10-31 2006-07-21 Arena Pharm Inc Tetrazole derivatives and methods of treatment of metabolic-related disorders thereof
US7834013B2 (en) 2003-11-19 2010-11-16 Glaxosmithkline Llc Aminophenylcyclopropyl carboxylic acids and derivatives as agonists to GPR40
CN1882557A (en) 2003-11-21 2006-12-20 艾尼纳制药公司 4-oxo-4,5-dihydro-furan-2-carboxylic and acid derivatives and methods of treatment of metabolic-related disorders thereof
TW200523247A (en) 2003-12-25 2005-07-16 Takeda Pharmaceutical 3-(4-benzyloxyphenyl) propanoic acid derivatives
JP4855777B2 (en) 2003-12-26 2012-01-18 武田薬品工業株式会社 Phenylpropanoic acid derivatives
US7786165B2 (en) 2004-03-15 2010-08-31 Takeda Pharmaceutical Company Limited Aminophenylpropanoic acid derivative
EP1731505B1 (en) 2004-03-30 2015-01-14 Takeda Pharmaceutical Company Limited Alkoxyphenylpropanoic acid derivatives
KR20070053659A (en) 2004-04-20 2007-05-25 도이체스 인스티튜트 퓌어 에른에룬그스포슝 Agents of bitter receptors and uses thereof
JP2007284350A (en) 2004-07-27 2007-11-01 Takeda Chem Ind Ltd Diabetes treatment
US20060024335A1 (en) 2004-07-29 2006-02-02 Roger Stier E Oral compositions which mask the bitter taste of a bitter-tasting agent
AU2005289810A1 (en) 2004-09-22 2006-04-06 Arena Pharmaceuticals, Inc. GPR43 and modulators thereof for the treatment of metabolic-related disorders
US20080021069A1 (en) 2004-10-08 2008-01-24 Takeda Pharmaceutical Company Limited Receptor Function Regulating Agent
WO2006052566A2 (en) 2004-11-03 2006-05-18 Arena Pharmaceuticals, Inc. Gpr41 and modulators thereof for the treatment of insulin-related disorders
EP1815015B1 (en) 2004-11-18 2012-05-23 Deutsches Institut für Ernährungsforschung Potsdam -Rehbrücke Stiftung des Öffentlichen Rechts Agonists of bitter taste receptors and uses thereof
PE20060949A1 (en) 2004-12-23 2006-10-11 Arena Pharm Inc FUSED DERIVATIVES OF PIRAZOLE AS NIACIN RECEPTOR AGONISTS
DOP2006000008A (en) 2005-01-10 2006-08-31 Arena Pharm Inc COMBINED THERAPY FOR THE TREATMENT OF DIABETES AND RELATED AFFECTIONS AND FOR THE TREATMENT OF AFFECTIONS THAT IMPROVE THROUGH AN INCREASE IN THE BLOOD CONCENTRATION OF GLP-1
US20080090865A1 (en) 2005-01-28 2008-04-17 Min Ge Antidiabetic Bicyclic Compounds
AU2006210954A1 (en) 2005-01-31 2006-08-10 Merck & Co., Inc. Antidiabetic bicyclic compounds
US20060222709A1 (en) * 2005-03-18 2006-10-05 Agi Therapeutics Research Ltd. Metformin methods and formulations for treating chronic constipation
WO2006102653A2 (en) 2005-03-24 2006-09-28 Irm Llc Methods and compositions for treating insulin resistance and obesity-induced diseases
WO2006118341A1 (en) 2005-04-28 2006-11-09 Ajinomoto Co., Inc. Novel lactam compound
EP1899304A1 (en) 2005-05-23 2008-03-19 Arena Pharmaceuticals, Inc. 5-amino-1h-pyrazole-3-carboxylic acid derivatives as agonists for the g-protein coupled receptor (gpcr) rup38 for the treatment of metabolic-related disorders thereof
US20060269617A1 (en) 2005-05-26 2006-11-30 Suracell, Inc. Supplement compositions and method of use for enhancement of insulin sensitivity
CA2612561A1 (en) 2005-06-22 2007-01-04 Senomyx, Inc. Identification of human t2r recepors that are activated by bitter molecules in coffee (chlorogenic lactones) and related assays for identifying human bitter taste modulators
WO2007014824A1 (en) 2005-07-28 2007-02-08 Nestec S.A. Fat taste receptors and their methods of use
JP5084503B2 (en) 2005-07-29 2012-11-28 武田薬品工業株式会社 Cyclopropanecarboxylic acid compound
US20090117559A1 (en) 2005-08-10 2009-05-07 Liaw Chen W Methods for Determining Probability of an Adverse or Favorable Reaction to a Niacin Receptor Agonist
WO2007026874A1 (en) 2005-09-02 2007-03-08 Eisai R & D Management Co., Ltd. Method for screening of substance effective on disease using gpr120 and phospholipase
WO2007049050A2 (en) 2005-10-27 2007-05-03 Heptahelix Ab Modulators of gpr40 for the treatment of diabetes
US20070104805A1 (en) 2005-11-01 2007-05-10 Udell Ronald G Compositions of Hoodia Gordonii and Pinolenic Acid Derivatives
JP2007215162A (en) 2006-01-11 2007-08-23 Canon Inc Information processing apparatus, control method therefor, program, and storage medium
US20070207227A1 (en) 2006-02-23 2007-09-06 Conopco, Inc., D/B/A Unilever, A Corporation Of New York Appetite suppressant compositions
US20090221639A1 (en) 2006-04-06 2009-09-03 Lisa Sarah Bertram Heterocyclic GPCR Agonists
WO2007116404A2 (en) 2006-04-10 2007-10-18 Bar-Ilan University Cucurbitacin glucosides and use thereof in treating cancer
GB0607196D0 (en) 2006-04-11 2006-05-17 Prosidion Ltd G-protein coupled receptor agonists
US7833730B2 (en) 2006-04-11 2010-11-16 Arena Pharmaceuticals, Inc. Methods of using GPR119 to identify compounds useful for increasing bone mass in an individual
PE20071221A1 (en) 2006-04-11 2007-12-14 Arena Pharm Inc GPR119 RECEPTOR AGONISTS IN METHODS TO INCREASE BONE MASS AND TO TREAT OSTEOPOROSIS AND OTHER CONDITIONS CHARACTERIZED BY LOW BONE MASS, AND COMBINED THERAPY RELATED TO THESE AGONISTS
TW200815377A (en) 2006-04-24 2008-04-01 Astellas Pharma Inc Oxadiazolidinedione compound
WO2007136572A2 (en) 2006-05-15 2007-11-29 Merck & Co., Inc. Antidiabetic bicyclic compounds
WO2007134613A1 (en) 2006-05-24 2007-11-29 Rheoscience A/S Modulation of gpr120 activity in adipocytes/fat tissue
ES2450081T3 (en) 2006-06-27 2014-03-21 Takeda Pharmaceutical Company Limited Condensed cyclic compounds as modulators of the GPR40 receptor
CA2551706A1 (en) 2006-06-27 2007-12-27 Innovative Life Sciences Corporation Herbal product comprising cinnamon and bitter melon
CN100596277C (en) 2006-07-10 2010-03-31 博仲盛景医药技术（北京）有限公司 Medicinal composition for promoting enterogastric peristalsis
CN101511429A (en) 2006-07-13 2009-08-19 史密丝克莱恩比彻姆公司 Indulines derivatives and gpr119 agonists
CN101505771A (en) 2006-08-17 2009-08-12 荷兰联合利华有限公司 Processes for production of HOODIA plant extracts containing steroidal glycosides
AP2009004773A0 (en) 2006-08-24 2009-02-28 Unilever Plc Process for preparing a composition comprising steroidal glycosides
CA2661371A1 (en) 2006-08-30 2008-03-06 Biovitrum Ab (Publ) Pyrimidine compounds for treating gpr119 related disorders
CN101522702A (en) 2006-09-05 2009-09-02 塞诺米克斯公司 Novel haplotype of human t2r receptor ht2r50 and its use in assays for identifying human bitter taste modulators
AU2007293028B2 (en) 2006-09-07 2012-05-31 Amgen Inc. Heterocyclic GPR40 modulators
WO2008063321A2 (en) 2006-10-13 2008-05-29 Janssen Pharmaceutica N.V. Gpr81-ligand complexes and their preparation and use
JP2010508268A (en) 2006-10-31 2010-03-18 メルク エンド カムパニー インコーポレーテッド Antidiabetic bicyclic compound
WO2008054674A2 (en) 2006-10-31 2008-05-08 Merck & Co., Inc. Antidiabetic bicyclic compounds
BRMU8602999U (en) * 2006-11-16 2008-07-08 Walter Junior Santos medicine "rosuvastatin + metformin" in combination form for cardiovascular disease
WO2008058355A2 (en) * 2006-11-16 2008-05-22 Walter Santos Junior Descriptive report of patent of invention of the medicament 'atorvastatin + metformin' in combined form for cardiovascular diseases
CN101190179B (en) * 2006-11-20 2010-05-12 北京利龄恒泰药业有限公司 Enteric medicinal composition for treating diabetes and preparation method thereof
TW200838526A (en) 2006-12-01 2008-10-01 Astellas Pharma Inc Carboxylic acid derivatives
JP5405120B2 (en) 2006-12-01 2014-02-05 Ｍｓｄ株式会社 Novel phenyl-isoxazol-3-ol derivatives
WO2008093984A1 (en) * 2007-01-29 2008-08-07 Hanall Pharmaceutical Company. Ltd N, n- dimethyl imidodicarbonimidic diamide acetate, method for producing the same and pharmaceutical compositions comprising the same
US20080186971A1 (en) 2007-02-02 2008-08-07 Tarari, Inc. Systems and methods for processing access control lists (acls) in network switches using regular expression matching logic
CN101663298A (en) 2007-02-22 2010-03-03 Irm责任有限公司 Thiazole derivatives as modulators of g protein-coupled receptors
JP2010520878A (en) 2007-03-08 2010-06-17 アイアールエム・リミテッド・ライアビリティ・カンパニー Compounds and compositions as modulators of GPR119 activity
EP1975612A1 (en) 2007-03-29 2008-10-01 Deutsches Institut für Ernährungsforschung Potsdam -Rehbrücke-Stiftung des öffentlichen Rechts- Vertreten durch den Stiftungsvorstand Agonists of bitter taste receptors and uses thereof
EP1975611A1 (en) 2007-03-29 2008-10-01 Deutsches Institut für Ernährungsforschung Potsdam -Rehbrücke-Stiftung des öffentlichen Rechts- Vertreten durch den Stiftungsvorstand Agonists of bitter taste receptors and uses thereof
EP2139843B1 (en) 2007-04-16 2013-12-25 Amgen, Inc Substituted biphenyl phenoxy-, thiophenyl- and aminophenylpropanoic acid gpr40 modulators
WO2008130615A1 (en) 2007-04-20 2008-10-30 Schering Corporation Tetrahydropyrido[4,3-d]pyrimidinone derivatives and methods of use thereof
CN101754961A (en) 2007-04-20 2010-06-23 先灵公司 Pyrimidinone derivatives and methods of use thereof
CA2684633A1 (en) 2007-04-20 2008-10-30 Schering Corporation Pyrimidinone derivatives and methods of use thereof
EP2151236A4 (en) 2007-04-26 2013-01-16 Japan Science & Tech Agency G PROTEIN COUPLED RECEPTOR AGONIST
EP2152707B1 (en) 2007-05-04 2012-06-20 Bristol-Myers Squibb Company [6,5]-bicyclic gpr119 g protein-coupled receptor agonists
ES2388967T3 (en) 2007-05-04 2012-10-22 Bristol-Myers Squibb Company Agonists [6,6] - and [6,7] -cyclics of the GPR119 receptor coupled to the G protein
US8309534B2 (en) 2007-05-15 2012-11-13 Medical College Of Georgia Research Institute, Inc. Compositions comprising a GPR109 ligand for treating disorders of the digestive tract and/or cancer
JP5318867B2 (en) 2007-07-17 2013-10-16 ブリストル−マイヤーズ スクイブ カンパニー Pyridone GPR119G protein coupled receptor agonist
KR20100033419A (en) 2007-07-19 2010-03-29 메타볼렉스, 인코포레이티드 N-azacyclic substituted pyrrole, pyrazole, imidazole, triazole and tetrazole derivatives as agonists of the rup3 or gpr119 receptor for the treatment of diabetes and metabolic disorders
US20090042813A1 (en) 2007-08-10 2009-02-12 Sergey Michailovich Melnikov Hoodia extract oil compositions comprising medium chain triglycerides
WO2009033078A2 (en) 2007-09-05 2009-03-12 Raif Tawakol Compositions and methods for controlling cholesterol levels
EP2200609A1 (en) 2007-09-10 2010-06-30 Prosidion Limited Compounds for the treatment of metabolic disorders
WO2009038204A1 (en) 2007-09-17 2009-03-26 Pharma Frontier Co., Ltd. Novel long-chain fatty acid derivative compound and g-protein-coupled receptor agonist containing the compound as active ingredient
CN101801954B (en) 2007-09-20 2013-10-09 Irm责任有限公司 Compounds and compositions as modulators of GPR119 activity
US8030354B2 (en) 2007-10-10 2011-10-04 Amgen Inc. Substituted biphenyl GPR40 modulators
GB0720389D0 (en) 2007-10-18 2008-11-12 Prosidion Ltd G-Protein Coupled Receptor Agonists
GB0720390D0 (en) 2007-10-18 2007-11-28 Prosidion Ltd G-Protein coupled receptor agonists
MX2010004450A (en) 2007-10-22 2010-05-05 Schering Corp Bicyclic heterocycle derivatives and methods of use thereof.
JP2011016722A (en) 2007-10-23 2011-01-27 Astellas Pharma Inc Thiazolidinedione compound
WO2009053980A2 (en) 2007-10-24 2009-04-30 Arava Hoodia Growers A. C. S. Ltd. An improved appetite suppressant
TW200932219A (en) 2007-10-24 2009-08-01 Astellas Pharma Inc Oxadiazolidinedione compound
JP5542058B2 (en) 2007-10-29 2014-07-09 メルク・シャープ・アンド・ドーム・コーポレーション Antidiabetic tricyclic compounds
CN101918014B (en) 2008-01-29 2012-06-20 中森制药株式会社 Medicinal composition
EA201001330A1 (en) 2008-02-22 2011-04-29 Айрм Ллк COMPOUNDS AND COMPOSITIONS AS GPR119 ACTIVITY MODULATORS
CA2714703A1 (en) 2008-02-22 2009-08-27 Irm Llc Compounds and compositions as modulators of gpr119 activity
WO2009105717A1 (en) 2008-02-22 2009-08-27 Irm Llc Compounds and compositions as modulators of gpr119 activity
WO2009106561A1 (en) 2008-02-27 2009-09-03 Biovitrum Ab (Publ) Pyrazine compounds for treating gpr119 related disorders
WO2009106565A1 (en) 2008-02-27 2009-09-03 Biovitrum Ab (Publ) Agonists of gpr119
WO2009117421A2 (en) 2008-03-17 2009-09-24 Kalypsys, Inc. Heterocyclic modulators of gpr119 for treatment of disease
BRPI0909469A2 (en) 2008-03-31 2015-12-29 Metabolex Inc aryl oxymethylene compounds and uses thereof
EP2146210A1 (en) 2008-04-07 2010-01-20 Arena Pharmaceuticals, Inc. Methods of using A G protein-coupled receptor to identify peptide YY (PYY) secretagogues and compounds useful in the treatment of conditions modulated by PYY
EP2271619A1 (en) 2008-04-07 2011-01-12 Irm Llc Compounds and compositions as modulators of gpr119 activity
WO2009125804A1 (en) 2008-04-09 2009-10-15 武田薬品工業株式会社 Screening method
CA2724426A1 (en) 2008-05-19 2009-11-26 Schering Corporation Bicyclic heterocycle derivatives and use thereof as gpr119 modulators
US8188098B2 (en) 2008-05-19 2012-05-29 Hoffmann-La Roche Inc. GPR119 receptor agonists
WO2009140784A1 (en) 2008-05-23 2009-11-26 Givaudan Sa Bitter alkaloid containing consumables comprising bitter blockers
WO2009151542A2 (en) 2008-05-27 2009-12-17 Duke University Nicotinic acid receptor ligands
CN101695575A (en) * 2008-05-29 2010-04-21 北京奥萨医药研究中心有限公司 Pharmaceutical composition containing statin-type lipid-lowering medicaments, phenformin-type hypoglycemic medicaments and nicotinic acid
WO2009147990A1 (en) 2008-06-02 2009-12-10 萬有製薬株式会社 Novel isoxazole derivative
WO2009150144A1 (en) 2008-06-10 2009-12-17 Inovacia Ab New gpr119modulators
US8546085B2 (en) 2008-06-13 2013-10-01 Givaudan Sa Methods of identifying modulators of the bitter taste receptor TAS2R44
JP2011524917A (en) 2008-06-20 2011-09-08 メタボレックス， インコーポレイテッド Aryl GPR119 agonists and uses thereof
GB0812031D0 (en) 2008-07-01 2008-08-06 7Tm Pharma As Thiazole derivatives
GB0812649D0 (en) 2008-07-10 2008-08-20 Prosidion Ltd Compounds
GB0812648D0 (en) 2008-07-10 2008-08-20 Prosidion Ltd Compounds
AU2009268527B2 (en) 2008-07-11 2012-11-01 Irm Llc 4-phenoxymethylpiperidines as modulators of GPR119 activity
TW201006821A (en) 2008-07-16 2010-02-16 Bristol Myers Squibb Co Pyridone and pyridazone analogues as GPR119 modulators
JP2011528365A (en) 2008-07-16 2011-11-17 シェーリング コーポレイション Bicyclic heterocyclic derivatives as GPR119 modulators and methods for their use
JP2012503595A (en) 2008-07-28 2012-02-09 シダンスク ユニバーシティ Compounds for the treatment of metabolic diseases
JPWO2010013849A1 (en) 2008-08-01 2012-01-12 日本ケミファ株式会社 GPR119 agonist
US8557530B2 (en) 2008-08-29 2013-10-15 Givaudan Sa Use of a TAS2R7 nucleic acid sequence to identify modulators
WO2010024393A1 (en) 2008-08-29 2010-03-04 サントリーホールディングス株式会社 Novel epigallocatechin gallate tetramer, and vascular endothelial function improver comprising same
MX2011002558A (en) 2008-09-10 2011-04-26 Boehringer Ingelheim Int Combination therapy for the treatment of diabetes and related conditions.
WO2010030360A1 (en) 2008-09-11 2010-03-18 Arena Pharmaceuticals, Inc. 3H-IMIDAZO[4,5-b]PYRIDIN-5-OL DERIVATIVES USEFUL IN THE TREATMENT OF GPR81 RECEPTOR DISORDERS
MX2011003917A (en) 2008-10-15 2011-05-31 Amgen Inc Spirocyclic gpr40 modulators.
WO2010048149A2 (en) 2008-10-20 2010-04-29 Kalypsys, Inc. Heterocyclic modulators of gpr119 for treatment of disease
MX2011004125A (en) 2008-10-21 2011-05-19 Metabolex Inc Aryl gpr120 receptor agonists and uses thereof.
WO2010060198A1 (en) 2008-11-26 2010-06-03 West Central Envirotech Inc. Composition and method for controlling insects
AR074760A1 (en) 2008-12-18 2011-02-09 Metabolex Inc GPR120 RECEIVER AGONISTS AND USES OF THE SAME IN MEDICINES FOR THE TREATMENT OF DIABETES AND METABOLIC SYNDROME.
WO2010074271A1 (en) 2008-12-26 2010-07-01 武田薬品工業株式会社 Therapeutic agent for diabetes
JP5597142B2 (en) 2009-01-03 2014-10-01 静岡県公立大学法人 Sulfated C-glycoside, isolation method and synthesis method thereof
TW201031668A (en) 2009-01-22 2010-09-01 Mitsubishi Tanabe Pharma Corp Novel pyrrolo[2,3-d] pyrimidine compound
WO2010085525A1 (en) 2009-01-23 2010-07-29 Schering Corporation Bridged and fused heterocyclic antidiabetic compounds
AU2010206783A1 (en) 2009-01-23 2011-07-28 Merck Sharp & Dohme Corp. Pentafluorosulpholane-containing antidiabetic compounds
AU2010206789A1 (en) 2009-01-23 2011-07-28 Merck Sharp & Dohme Corp. Bridged and fused antidiabetic compounds
WO2010088518A2 (en) 2009-01-31 2010-08-05 Kalypsys, Inc. Heterocyclic modulators of gpr119 for treatment of disease
TW201040186A (en) 2009-02-05 2010-11-16 Schering Corp Phthalazine-containing antidiabetic compounds
JP5657518B2 (en) 2009-02-18 2015-01-21 武田薬品工業株式会社 Fused heterocyclic compounds
GB0904285D0 (en) 2009-03-12 2009-04-22 Prosidion Ltd Compounds for the treatment of metabolic disorders
GB0904287D0 (en) 2009-03-12 2009-04-22 Prosidion Ltd Compounds for the treatment of metabolic disorders
GB0904284D0 (en) 2009-03-12 2009-04-22 Prosidion Ltd Compounds for the treatment of metabolic disorders
JP2012520868A (en) 2009-03-20 2012-09-10 ファイザー・インク 3-Oxa-7-azabicyclo [3.3.1] nonane
JP2012136438A (en) 2009-04-22 2012-07-19 Astellas Pharma Inc Tetrazole compound
EP2423176A4 (en) 2009-04-22 2012-11-07 Astellas Pharma Inc Carboxylic acid compound
JP2012136439A (en) 2009-04-24 2012-07-19 Nippon Chemiphar Co Ltd Diazaspiroalkane derivative
CA2759891A1 (en) 2009-05-08 2010-11-11 Pfizer Inc. Gpr 119 modulators
CA2759843A1 (en) 2009-05-08 2010-11-10 Pfizer Inc. Gpr 119 modulators
JP2012528847A (en) 2009-06-05 2012-11-15 ファイザー・インク L- (piperidin-4-yl) -pyrazole derivatives as GPR119 modulators
WO2010143733A1 (en) 2009-06-09 2010-12-16 Takeda Pharmaceutical Company Limited Novel fused cyclic compound and use thereof
AR077642A1 (en) 2009-07-09 2011-09-14 Arena Pharm Inc METABOLISM MODULATORS AND THE TREATMENT OF DISORDERS RELATED TO THE SAME
AR077638A1 (en) 2009-07-15 2011-09-14 Lilly Co Eli COMPOSITE OF (METHANOSULPHONYL -PIPERIDIN) - (ALCOXI-ARIL) -TETRAHIDRO- PYRIDINE, PHARMACEUTICAL COMPOSITION THAT INCLUDES IT AND ITS USE TO PREPARE A USEFUL MEDICINAL PRODUCT FOR THE TREATMENT OF DIABETES OR OBESITY
US8709745B2 (en) 2009-07-28 2014-04-29 Deutsches Institut Für Ernährungsforschung Potsdam-Rehbrücke Methods for isolating ligands of the human bitter taste receptor TAS2R49
WO2011014520A2 (en) 2009-07-29 2011-02-03 Irm Llc Compounds and compositions as modulators of gpr119 activity
US20120245344A1 (en) 2009-08-31 2012-09-27 Nippon Chemiphar Co., Ltd. Gpr119 agonist
RU2569063C2 (en) 2009-09-01 2015-11-20 Катабэйсис Фармасьютикалз, Инк. Conjugates of fatty acids and niacin and application thereof
WO2011030139A1 (en) 2009-09-11 2011-03-17 Astrazeneca Ab 4- (pyrimidin-2-yl) -piperazine and 4- (pyrimidin-2-yl) -piperidine derivatives as gpr119 modulators
WO2011036576A1 (en) 2009-09-23 2011-03-31 Pfizer Inc. Gpr 119 modulators
US20110082202A1 (en) 2009-10-05 2011-04-07 Milne Jill C Fatty acid acifran derivatives and their uses
WO2011044136A1 (en) 2009-10-05 2011-04-14 Catabasis Pharmaceuticals, Inc. Fatty acid acipimox derivatives and their uses
KR20120104534A (en) 2009-10-06 2012-09-21 브리스톨-마이어스 스큅 컴퍼니 Pyrrolidine gpr40 modulators
CN102686579A (en) 2009-10-09 2012-09-19 Irm责任有限公司 Compounds and compositions as modulators of GPR119 activity
US20120202849A1 (en) * 2009-10-12 2012-08-09 Anil Pareek Pharmaceutical compositions for the treatment/prophylaxis of non-alcoholic fatty liver disease
EP2490695B1 (en) 2009-10-21 2013-11-20 Wisconsin Alumni Research Foundation Method of preventing type 1 diabetes
WO2011053688A1 (en) 2009-10-29 2011-05-05 Schering Corporation Bridged bicyclic piperidine derivatives and methods of use thereof
JPWO2011052756A1 (en) 2009-10-30 2013-03-21 持田製薬株式会社 Novel 3-hydroxy-5-arylisoxazole derivatives
WO2011057110A1 (en) 2009-11-06 2011-05-12 Ruprecht-Karls-Universitat-Heidelberg Gpr109a agonists for the treatment of cerebral ischemia
WO2011055770A1 (en) 2009-11-06 2011-05-12 武田薬品工業株式会社 Fused heterocyclic compound
JP2013511571A (en) 2009-11-23 2013-04-04 ファイザー・インク Imidazo-pyrazoles as GPR119 inhibitors
US9301929B2 (en) 2009-11-24 2016-04-05 Merck Sharp & Dohme Corp. Substituted biaryl derivatives and methods of use thereof
EP2689805A1 (en) 2009-12-04 2014-01-29 Colgate-Palmolive Company Oral compositions containing extracts of garcinia mangostana l. and related methods
EP2332427A1 (en) 2009-12-07 2011-06-15 Nestec S.A. low caloric fat replacers
WO2011072132A1 (en) 2009-12-09 2011-06-16 The Regents Of The University Of California Methods of treating inflammatory conditions
SMT201800004T1 (en) 2009-12-18 2018-03-08 Ogeda Sa Pyrrolidine carboxylic acid derivatives as agonists of g-protein coupled receptor 43 (gpr43), pharmaceutical composition and methods for use in treating metabolic disorders
JP2013047188A (en) 2009-12-24 2013-03-07 Nippon Chemiphar Co Ltd Gpr119 agonist
US8476287B2 (en) 2009-12-25 2013-07-02 Mochida Pharmaceutical Co., Ltd. 3-hydroxy-5-arylisothiazole derivative
EP2345646A1 (en) 2010-01-14 2011-07-20 InterMed Discovery GmbH Use of tricyclic sesquiterpene lactones in the treatment of obesity and related diseases and non-therapeutic treatable conditions
WO2011092284A1 (en) 2010-01-29 2011-08-04 Euroscreen S.A. Novel amino acid derivatives and their use as gpr43 receptor modulators
WO2011093501A1 (en) 2010-02-01 2011-08-04 日本ケミファ株式会社 Gpr119 agonist
CN101785763B (en) * 2010-02-04 2011-11-23 贵州天安药业股份有限公司 Metformin hydrochloride enteric-coated sustained release tablet and preparation method thereof
WO2011113947A1 (en) 2010-03-18 2011-09-22 Boehringer Ingelheim International Gmbh Combination of a gpr119 agonist and the dpp-iv inhibitor linagliptin for use in the treatment of diabetes and related conditions
JP2013523819A (en) 2010-04-06 2013-06-17 アリーナ ファーマシューティカルズ， インコーポレイテッド GPR119 receptor modulators and treatment of disorders related thereto
CN102933576A (en) 2010-04-08 2013-02-13 百时美施贵宝公司 Pyrimidinylpiperidinyloxypyridinone analogs as GPR119 modulators
GB201006166D0 (en) 2010-04-14 2010-05-26 Prosidion Ltd Compounds for the treatment of metabolic disorders
GB201006167D0 (en) 2010-04-14 2010-05-26 Prosidion Ltd Compounds for the treatment of metabolic disorders
BR112012028445A2 (en) 2010-05-06 2016-07-19 Bristol Myers Squibb Co bicyclic heteroaryl compounds as gpr119 modulators
US8729084B2 (en) 2010-05-06 2014-05-20 Bristol-Myers Squibb Company Benzofuranyl analogues as GPR119 modulators
EP2566864B1 (en) 2010-05-07 2014-09-03 Boehringer Ingelheim International GmbH Pyridazinones as gpr119 agonists
RU2012154308A (en) 2010-05-17 2014-06-27 Эррэй Биофарма Инк. PIPERIDINYL-SUBSTITUTED LACTAMS AS GPR119 MODULATORS
WO2011145718A1 (en) 2010-05-21 2011-11-24 田辺三菱製薬株式会社 Novel pyrrolo[2,3-d]pyrimidine compound
TW201202230A (en) 2010-05-24 2012-01-16 Mitsubishi Tanabe Pharma Corp Novel quinazoline compound
US20110293753A1 (en) 2010-05-28 2011-12-01 Louis Bellafiore Tocotrienol Compositions
TW201209054A (en) 2010-05-28 2012-03-01 Prosidion Ltd Novel compounds
WO2011151436A2 (en) 2010-06-04 2011-12-08 Euroscreen S.A. Novel compounds, method for use them and pharmaceutical composition containing them
GB201009873D0 (en) 2010-06-14 2010-07-21 Univ Leuven Kath Method for hydrogenation of isoalpha-acids (isohumulones) to hexahydro-iso-alpha-acids (hexahydro-isohumulones) by using heterogeneous ruthenium
JP5746334B2 (en) 2010-06-16 2015-07-08 シマベイ セラピューティクス， インコーポレーテッド GPR120 receptor agonist and use thereof
US20130096141A1 (en) 2010-06-18 2013-04-18 Bernard R. Neustadt Bicyclic heterocycle derivatives and methods of use thereof
EP2397039A1 (en) 2010-06-21 2011-12-21 Abbott Laboratories Compositions for delaying progression of diabetes using Salacia oblonga extract
US8530413B2 (en) 2010-06-21 2013-09-10 Sanofi Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
TW201215388A (en) 2010-07-05 2012-04-16 Sanofi Sa (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
TW201221505A (en) 2010-07-05 2012-06-01 Sanofi Sa Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
WO2012006955A1 (en) 2010-07-14 2012-01-19 Zhejiang Beta Pharma Inc. Compounds for treatment of metabolic disorders
EP2595952B1 (en) 2010-07-23 2020-11-18 Connexios Life Sciences Pvt. Ltd. Agonists of gpr40
KR20120011357A (en) 2010-07-23 2012-02-08 현대약품 주식회사 Substituted pyridinone derivatives and preparation method thereof
WO2012025811A1 (en) 2010-08-23 2012-03-01 Lupin Limited Indolylpyrimidines as modulators of gpr119
US20130184257A1 (en) 2010-09-17 2013-07-18 Thomas Daniel Aicher Piperidinyl-substituted lactams as gpr119 modulators
EP2619198A1 (en) 2010-09-22 2013-07-31 Arena Pharmaceuticals, Inc. Modulators of the gpr119 receptor and the treatment of disorders related thereto
CN102432598A (en) 2010-09-29 2012-05-02 江苏恒瑞医药股份有限公司 Tricyclic compound, preparation method thereof and pharmaceutical application thereof
JP5809157B2 (en) 2010-10-08 2015-11-10 持田製薬株式会社 Cyclic amide derivative
JP2014001144A (en) 2010-10-08 2014-01-09 Nippon Chemiphar Co Ltd Gpr119 agonist
DK2625177T3 (en) 2010-10-08 2015-10-12 Cadila Healthcare Ltd New GPR 119 agonists
CN101978956B (en) * 2010-10-13 2012-03-28 北京京丰制药有限公司 Metformin hydrochloride enteric-coated tablets and preparation method thereof
CA2853974C (en) 2010-10-30 2020-11-10 Kindex Therapeutics, Llc Cis 3,4-dihydroxy-2-(3-methylbutanoyl)-5-(3-methylbutyl)-4-(4-methylpentanoyl)cyclopent-2-en-1-one derivatives, substantially enantiomerically pure compositions and methods
CN103298801A (en) 2010-11-23 2013-09-11 辉瑞大药厂 4- (5-cyano-pyrazol-1-yl) -piperidine derivatives as GPR 119 modulators
EP2643311A1 (en) 2010-11-26 2013-10-02 Lupin Limited Bicyclic gpr119 modulators
UY33758A (en) 2010-12-01 2012-06-29 Boehringer Ingelheim Int INDANILOXIDIHIDROBENZOFURANILACETIC ACIDS
WO2012077655A1 (en) 2010-12-07 2012-06-14 塩野義製薬株式会社 Spiro derivative having gpr119 agonist activity
UY33805A (en) 2010-12-17 2012-07-31 Boehringer Ingelheim Int ? Dihydrobenzofuranyl-piperidinyl, aza-dihydrobenzofuranylpiperidinyl and diaza-dihydrobenzofuranyl-piperidinyl derivatives, pharmaceutical compositions containing them and uses thereof?
CN103328482A (en) 2011-01-03 2013-09-25 韩美药品株式会社 New bicyclic compound for modulating G protein-coupled receptors
US8778926B2 (en) 2011-01-21 2014-07-15 Boehringer Ingelheim International Gmbh Compounds, pharmaceutical compositions and uses thereof
CN102617548A (en) 2011-01-31 2012-08-01 北京赛林泰医药技术有限公司 Bicycloheteroaryl compounds as GPR Receptor stimulant, compositions and application thereof
TW201309639A (en) 2011-02-17 2013-03-01 Lg Life Sciences Ltd Oxime derivatives as GPR119 agonists
WO2012123449A1 (en) 2011-03-14 2012-09-20 Boehringer Ingelheim International Gmbh N- cyclopropyl - n- piperidinylbenzamides as gpr119 modulators
US20140018371A1 (en) 2011-04-01 2014-01-16 Arena Pharmaceuticals, Inc. Modulators Of The GPR119 Receptor And The Treatment Of Disorders Related Thereto
HK1207853A1 (en) 2011-04-08 2016-02-12 卡尔丹治疗有限公司 Ortho-fluoro substituted compounds for the treatment of metabolic diseases
US20140066369A1 (en) 2011-04-19 2014-03-06 Arena Pharmaceuticals, Inc. Modulators Of The GPR119 Receptor And The Treatment Of Disorders Related Thereto
WO2012145603A1 (en) 2011-04-22 2012-10-26 Arena Pharmaceuticals, Inc. Modulators of the gpr119 receptor and the treatment of disorders related thereto
US20140051714A1 (en) 2011-04-22 2014-02-20 Arena Pharmaceuticals, Inc. Modulators Of The GPR119 Receptor And The Treatment Of Disorders Related Thereto
US8557766B2 (en) 2011-04-27 2013-10-15 Mochida Pharmaceutical Co., Ltd. 3-hydroxyisothiazole 1-oxide derivatives
AU2012248627A1 (en) 2011-04-28 2013-11-14 Mochida Pharmaceutical Co., Ltd. Cyclic amide derivative
WO2012154009A2 (en) 2011-05-12 2012-11-15 한국화학연구원 Thienopyrimidine derivatives, pharmaceutically acceptable salts thereof, method for preparing thienopyrimidine derivatives, and pharmaceutical composition containing thienopyrimidine derivatives as active ingredients for preventing or treating diabetes-related diseases
WO2012170702A1 (en) 2011-06-08 2012-12-13 Arena Pharmaceuticals, Inc. Modulators of the gpr119 receptor and the treatment of disorders related thereto
JP6094578B2 (en) 2011-06-09 2017-03-15 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Substituted piperidines as GPR119 modulators for the treatment of metabolic disorders
JP2014159376A (en) 2011-06-17 2014-09-04 Taisho Pharmaceutical Co Ltd Azaspiroalkane compound
CA2841757A1 (en) 2011-07-15 2013-01-24 Etzer Darout Gpr 119 modulators
WO2013055910A1 (en) 2011-10-12 2013-04-18 Arena Pharmaceuticals, Inc. Modulators of the gpr119 receptor and the treatment of disorders related thereto
CN102357088A (en) * 2011-10-26 2012-02-22 河北山姆士药业有限公司 Metformin hydrochloride enteric-coated tablet

Also Published As

Publication number Publication date
JP2018087214A (en) 2018-06-07
WO2014011926A1 (en) 2014-01-16
CA2878625A1 (en) 2014-01-16
CN104780915A (en) 2015-07-15
EP2872127A1 (en) 2015-05-20
JP2015522080A (en) 2015-08-03
IL236647A0 (en) 2015-02-26
AU2013290100A1 (en) 2015-01-29
HK1210825A1 (en) 2016-05-06

Similar Documents

Publication Publication Date Title
AR091739A1 (en) COMPOSITIONS AND METHODS TO REDUCE CARDIOMETABOLIC RISK
UY35040A (en) PIRROLOPIRIMIDINILAMINO-BENZOTIAZOLONAS REPLACED
GT201200276A (en) COMBINATIONS OF ACTIVE COMPOUNDS
CL2014000601A1 (en) Topical veterinary composition comprising at least one active agent derived from isoxazoline; and use of the composition for the treatment or prevention of an infestation or infection by parasites in an animal.
CL2014002087A1 (en) Chewable veterinary composition comprising as active agent an isoxazoline derivative compound; and its use for the treatment and / or prevention of an infestation and / or infection by parasites in an animal.
BR112012023021A2 (en) indazole compounds and their uses
MX370664B (en) SELECTIVE GLUCOSE-REGULATED PROTEIN 94 (GPR94) INHIBITORS AND USES OF THEM.
NI201500094A (en) SUBSTITUTE COMPOUNDS FOR PYRROLOPYRIMIDINE, COMPOSITIONS OF THE SAME, AND METHODS OF TREATMENT THEREOF.
CU24336B1 (en) IMIDAZOPIRROLIDINONA COMPOUNDS
UY33598A (en) IMIDAZOPIRIDAZINAS REPLACED
MX393610B (en) Combination therapy including an mdm2 inhibitor and one or more additional pharmaceutically active agents for the treatment of cancers
MX392839B (en) SELF-REGULATED RELEASE OF ACTIVE PHARMACEUTICAL INGREDIENT.
MX346861B (en) CARCINOMA HEPATO CELLULAR TREATMENT METHODS.
PE20142314A1 (en) INTRANASAL COMPOSITIONS OF DEXMEDETOMIDINE AND METHODS OF USE OF THEM
DOP2016000253A (en) NEW COMPOUNDS
MX2015011316A (en) Substituted imidazopyridazines.
UY33984A (en) USE OF 2,3-DIHYDROIMIDAZO [1,2-C] SUBSTITUTED KINAZOLINS
DOP2016000007A (en) SUBSTITUTED PIRAZOLPIRIDINS
CO6741223A2 (en) Azetidine derivatives useful for the treatment of metabolic and inflammatory diseases
MX2016008429A (en) DERIVED FROM PIRANOCROMENIL PHENOL, AND PHARMACEUTICAL COMPOSITION TO TREAT A METABOLIC SYNDROME OR INFLAMMATORY DISEASE.
DOP2016000118A (en) TIENOPIRIMIDINS AS MKNK1 AND MKNK2 INHIBITORS
CO6551731A2 (en) COMPOSITION OF COMBINATION UNDERSTANDING AS ACTIVE INGREDIENT L- CARNITINE OR PROPIONIL L-CARNITINE, FOR THE PREVENTION OR TREATMENT OF CRITICAL VENOUS INSUFFICIENCY
SV2017005466A (en) PIRAZOLPIRIDINAMINS AS INHIBITORS OF MKNK1 AND MKNK2
CL2018003596A1 (en) Parasiticidal compositions comprising benzimidazole derivatives, methods and uses thereof. (divisional application 201402831)
CL2016000300A1 (en) Therapeutic methods

Legal Events

Date Code Title Description
FB Suspension of granting procedure